Emergency Department, Short Stay Unit and Hospitalization at Home Unit, Dr, Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
Unitat de Suport a La Recerca de Barcelona, Fundació Institut Universitari Per a La Recerca a l'Atenció Primària de Salut Jordi Gol I Gurina (IDIAPJGol), Catalan Institute of Health, Pompeu Fabra University, Barcelona, Spain.
Intern Emerg Med. 2022 Oct;17(7):2129-2140. doi: 10.1007/s11739-022-03068-9. Epub 2022 Aug 29.
The HEFESTOS scale was developed in 14 Spanish primary care centres and validated in 9 primary care centres of other European countries. It showed good performance to predict death/hospitalisation during the first 30 days after an episode of acute heart failure (AHF), with c-statistics of 0.807/0.730 in the derivation/validation cohorts. We evaluated this scale in the emergency department (ED) setting, comparing it to the EHMRG and MEESSI scales in the ED and the EFFECT and GWTG scales in hospitalised patients, to predict 30-day outcomes, including death and hospitalisation. Consecutive AHF patients were enrolled in 34 Spanish EDs in January-February 2016, 2018, and 2019 with variables needed to calculate outcome scores. Thirty-day hospitalisation/death (together and separately) and post-discharge combined adverse event (ED revisit or hospitalisation for AHF or all-cause death) were determined for patients discharged home after ED care. Predictive capacity was assessed by c-statistic with 95% confidence intervals. Of 10,869 patients, 4,044 were included (median age: 83 years, 54% women). The performance of HEFESTOS was modest for 30-day hospitalisation/death, c-statistic=0.656 (0.637-0.675), hospitalisation, 0.650 (0.631-0.669), and death, 0.610 (0.576-0.644). Of 1,034 patients with scores for the 5 scales, HEFESTOS had the numerically highest c-statistic for hospitalisation/death at 30 days, 0.666 (0.627-0.704), vs. MEESSI= 0.650 (0.612-0.687, p=0.51), EFFECT=0.633 (0.595-0.672, p=0.21), GWTG=0.618 (0.578-0.657, p=0.06) and EHMRG=0.617 (0.577-0.704, p=0.07). Similar modest performances were observed for predicting hospitalisation [ranging from HEFESTOS=0.656 (0.618-0.695) to GWTG=0.603 (0.564-0.643)]. Conversely, prediction of 30-day death was good with the MEESSI=0.787 (0.728-845), EFFECT=0.754 (0.691-0.818) and GWTG=0.749 (0.689-0.809) scales, and modest with EHMRG=0.649 (0.581-0.717) and HEFESTOS=0.610 (0.538-0.683). Although the HEFESTOS scale was numerically better for predicting 30-day hospitalisation/death in ED AHF patients, its modest performance precludes routine use. Only 30-day mortality was adequately predicted by some scales, with the MEESSI achieving the best results.
HEFESTOS 量表由 14 家西班牙初级保健中心开发,并在其他 9 个欧洲国家的初级保健中心进行了验证。它在预测急性心力衰竭(AHF)发作后 30 天内的死亡/住院方面表现出良好的性能,推导/验证队列的 C 统计量分别为 0.807/0.730。我们在急诊科(ED)环境中评估了该量表,将其与 ED 的 EHMRG 和 MEESSI 量表以及住院患者的 EFFECT 和 GWTG 量表进行比较,以预测包括死亡和住院在内的 30 天结局。2016 年 1 月至 2 月,34 家西班牙 ED 连续收治 AHF 患者,需要计算结局评分的变量。对于 ED 治疗后出院回家的患者,确定 30 天住院/死亡(合并和单独)和出院后复合不良事件(ED 再就诊或因 AHF 或全因死亡而住院)。通过 95%置信区间的 C 统计量评估预测能力。在 10869 名患者中,纳入 4044 名患者(中位年龄:83 岁,54%为女性)。HEFESTOS 对 30 天住院/死亡、C 统计量=0.656(0.637-0.675)、住院、0.650(0.631-0.669)和死亡、0.610(0.576-0.644)的预测性能较差。在 1034 名有 5 个量表评分的患者中,HEFESTOS 在 30 天的住院/死亡方面具有最高的数值 C 统计量,为 0.666(0.627-0.704),而 MEESSI=0.650(0.612-0.687,p=0.51),EFFECT=0.633(0.595-0.672,p=0.21),GWTG=0.618(0.578-0.657,p=0.06)和 EHMRG=0.617(0.577-0.704,p=0.07)。在预测住院方面也观察到类似的中等表现[范围从 HEFESTOS=0.656(0.618-0.695)到 GWTG=0.603(0.564-0.643)]。相反,MEESSI=0.787(0.728-845)、EFFECT=0.754(0.691-0.818)和 GWTG=0.749(0.689-0.809)量表对预测 30 天死亡具有良好的效果,EHMRG=0.649(0.581-0.717)和 HEFESTOS=0.610(0.538-0.683)的效果中等。尽管 HEFESTOS 量表在预测 ED AHF 患者 30 天住院/死亡方面具有较高的数值,但预测效果较差,因此不能常规使用。只有一些量表能够充分预测 30 天死亡率,其中 MEESSI 取得了最佳结果。